<DOC>
	<DOCNO>NCT02400346</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability brexpiprazole adjunctive treatment elderly population major depressive disorder inadequate response antidepressant treatment</brief_summary>
	<brief_title>Evaluation Safety Adjunct Brexpiprazole Elderly Patients With Major Depressive Disorder Inadequate Response Antidepressant Treatment</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>Main • The patient man woman age ≥65 yr The patient Major Depressive Disorder accord Diagnostic Statistical Manual Mental Disorders , 4th edition , Text Revision ( DSMIVTR™ ) . The patient inadequate response least one adequate antidepressant treatment current Major Depressive Episode ( MDE ) . The patient current MDE ≥8 week The patient currently treat protocol specify ADT least 6 week The patient judge benefit adjunctive treatment brexpiprazole accord clinical opinion investigator . Montgomery Åsberg Depression Rating Scale ( MADRS ) total score &gt; 18 screen baseline Clinical Global Impression Severity ( CGIS ) total score ≥3 screen baseline Main • The patient clinically significant unstable illness The patient newly diagnose unstable diabetes The patient Mini Mental State Exam ( MMSE ) score &lt; 24 The patient receive Transcranial Magnetic Stimulation ( TMS ) and/or electroconvulsive therapy ( ECT ) less 6 month prior Screening . The patient , opinion investigator base ColumbiaSuicide Severity Rating Scale ( CSSRS ) Suicidal Ideation behaviour rating , significant risk suicide Other protocol define inclusion exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>